AIM-2: A novel tumor antigen is expressed and presented by human glioma cells

Journal of Immunotherapy

Volumn 27, Issue 3, 2004, Pages 220-226

  Liu, Gentao ^a   Yu, John S ^a   Zeng, Gang ^b   Yin, Dong ^a   Xie, Dong ^a,c   Black, Keith L ^a   Ying, Han ^a,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d BAYER AG   (Germany)

Author keywords

AIM 2; Cytotoxic T lymphocyte; Dendritic cells; Glioblastoma multiforme; Tumor antigen

Indexed keywords

ANTIGEN ISOLATED FROM IMMUNOSELECTED MELANOMA 2; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; HLA A1 ANTIGEN; MESSENGER RNA; SYNTHETIC PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA SYNTHESIS; GENE EXPRESSION; GLIOMA CELL; HLA TYPING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

EID: 4344706290     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200405000-00006     Document Type: Article

References (32)

1. Black KL, Pikul BK. Gliomas-past, present, and future. Clin Neurosurg. 1999;45:160-163.
2. Surawicz TS, Davis F, Freels S. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 1998;40:151-160.
3. Rosenberg SA, Packard BS, Aebersold PM. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319: 1676-1680.
4. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10:281-287.
5. van der Bruggen P, Traversari C, Chomez P, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.
6. Van den Eynde B, Peeters O, De Backer O. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995;182:689-698.
7. Boel P, Wildmann C, Sensi ML. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995;2:167-175.
8. Wolfel T, Hauer M, Schneider J. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269:1281-1284.
9. Robbins PF, El-Gamil M, Li YF. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183:1185-1192.
10. Coulie PG, Lehmann F, Lethe B. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA. 1995;92:7976-7980.
11. Fisk B, Blevins TL, Wharton JT. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995;181:2109-2117.
12. Kawakami Y, Eliyahu S, Sakaguchi K. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180:347-352.
13. Kawakami Y, Eliyahu S, Jennings C. Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995;154:3961-3968.
14. Salgaller ML, Afshar A, Marincola FM. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 1995;55:4972-4979.
15. Wang RF, Parkhurst MR, Kawakami Y. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med. 1996;183:1131-1140.
16. Wang RF, Appella E, Kawakami Y. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996; 184:2207-2216.
17. Chi DD, Merchant RE, Rand R. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol. 1997;150:2143-2152.
18. Scarcella DL, Chow CW, Gonzales MF. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res. 1999;5:335-341.
19. Sahin U, Koslowski M, Tureci O. Expression of cancer testis genes in human brain tumors. Clin Cancer Res. 2000;6:3916-3922.
20. Schwechheimer K, Laufle RM, Schmahl W. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol. 1994;25:772-780.
21. Hiesiger EM, Hayes RL, Pierz DM. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol. 1993;16:93-104.
22. O I. Blaszczyk-Thurin M, Shen CT. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther. 2003;10:678-688.
23. Prins RM. Odesa SKLiau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 2003;63:8487-8491.
24. Liu G, Khong HT, Wheeler CJ. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother. 2003;26:301-312.
25. Harada M, Li YF, El-Gamil M, Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J Immunother. 2001;24:323-333.
26. Pellat-Deceunynck C, Mellerin MP, Labarriere N. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol. 2000;30:803-809,
27. Yu JS, Wheeler CJ, Zeltzer PM. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61:842-847.
28. Mayrand SG. WR. Non-traditional derived CTL epitopes: exceptions that prove the rules? Immunol Today. 1998;19:551-556.
29. Ronsin C, Chung-Scott V, Poullion I. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol. 1999;163:483-490.
30. Wang RF, Johnston SL, Zeng G. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998;161:3598-3606.
31. Ehtesham M, Samoto K, Kabos P. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther. 2002;9:925-934.
32. Kruse CA, Cepeda L, Owens B. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother. 1997;45:77-87.